Vor Biopharma (VOR) Operating Leases (2020 - 2026)

Vor Biopharma (VOR) has 7 years of Operating Leases data on file, last reported at $2.6 million in Q1 2026.

• On a quarterly basis, Operating Leases fell 90.07% year-over-year to $2.6 million in Q1 2026; TTM through Mar 2026 was $2.6 million, a 90.07% decrease from a year earlier, with the FY2025 full-year figure at $2.7 million, down 90.15% from the prior year.
• Operating Leases for Q1 2026 stood at $2.6 million, down from $2.7 million in the prior quarter.
• Over the last five years, Operating Leases for VOR reached as high as $37.4 million in Q2 2022 and fell as low as $2.6 million in Q1 2026.
• Historically, Operating Leases has averaged $26.0 million across 5 years, with a median of $30.2 million in 2024.
• Across the five-year window, Operating Leases soared 123.41% in 2022 and sank 90.22% in 2025, its largest moves.
• Year by year, Operating Leases stood at $35.6 million in 2022, then dropped by 10.69% to $31.8 million in 2023, then slipped by 13.24% to $27.6 million in 2024, then sank by 90.15% to $2.7 million in 2025, then decreased by 3.24% to $2.6 million in 2026.
• Per Business Quant data, the three most recent Operating Leases figures were $2.6 million in Q1 2026, $2.7 million in Q4 2025, and $2.8 million in Q3 2025.